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CHAPTER I 
 
Introduction 
 
Hemiketal eicosanoids (HKs), novel endogenous eicosanoids characterized by Claus 
Schneider’s lab, are produced when 5-lipoxygenase (5-LOX) oxygenates arachidonic acid to 
form 5S-hydroperoxyeicosatetraenoic acid (5S-HPETE)1,2. A reduction product of 5S-HPETE, 5-
hydroxyeicosatetraenoic acid (5S-HETE) serves as an efficient substrate for cyclooxygenase-2 
(COX-2) (but not cyclooxygenase-1) and leads to the formation of a relatively unstable 
diendoperoxide (diEP)1,2. COX-2 uses 3 molecules of oxygen to convert 5S-HETE to the diEP. 
The diEP non-enzymatically rearranges to form a mixture of HKs, termed HKE2 and HKD2 
based on their similarity in structure to prostaglandin E2 and prostaglandin D2.  HKD2 also forms 
enzymatically when the diEP acts as a substrate for hematopoietic prostaglandin D synthase (H-
PGDS)1,2. The H-PGDS opens both endoperoxides to form an open chain intermediate that 
rearranges to HKD2
2 (Figure 1). The convergence of 5-LOX and COX-2 pathways suggests a 
novel mechanism for integrating signaling by both pathways and may have important 
implications for understanding of inflammation and mechanisms affecting COX-2 inhibition. 
With HKE2 now available synthetically, the goal of this project was to begin elucidating the 
biological activity of HKE2 in primary synovial fibroblasts, human umbilical vein endothelial 
cells (HUVECs), and RAW 264.7 cells, each cell type chosen specifically for its relevance to 
inflammation.  
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Since HKs are formed in the same physiological context (and by the same biosynthetic 
enzymes) as prostaglandins (PGs) and leukotrienes (LTs), I hypothesized that the HKE2 would 
function in a similar manner: as an autocrine and/or paracrine signaling molecule that mediates  
 
  
Figure 1: Hemiketal Eicosanoid Biosynthetic Pathway. Hemiketal eicosanoids 
(HKs) are formed when 5-lipoxygenase (5-LOX) oxygenates arachidonic acid to 
form 5S-hydroperoxyeicosatetraenoic acid (5S-HPETE)1,2. 5-
hydroxyeicosatetraenoic acid (5S-HETE), a reduction product of 5S-HPETE serves 
as an efficient substrate for cyclooxygenase-2 (COX-2) and leads to the formation of 
a relatively unstable diendoperoxide (diEP)1,2. COX-2 uses 3 molecules of oxygen to 
convert 5S-HETE to the diEP, which is non-enzymatically rearranged to form a 
mixture of HKs, termed HKE2 and HKD2 for their similarity in structure to 
prostaglandin E2 and prostaglandin D2.  HKD2 is also formed enzymatically when 
the diEP acts as a substrate for H-PGDS1,2. H-PGDS opens both endoperoxides to 
form an open chain intermediate that rearranges to HKD2
1,2 
3 
 
biological activity within the cell of origin, or the nearby environment. I hypothesized that HKE2 
would play a role in the regulation of inflammation and therefore examined its action as a G-
protein coupled receptor ligand, in phagocytosis, tubulogenesis, and signaling. HKE2 is a newly 
characterized molecule, and as such I have defined some basic parameters relating to its 
formation and localization.  
  
Pathways of enzymatic arachidonic acid oxygenation 
The activity of both 5-LOX and COX-2 are required for the formation of HKs. With the 
biological function of HKs largely uncharacterized, it is important to discuss the products of 5-
LOX and COX-2 individually, as a background for the examination of HK function. 
Leukotrienes  (LTs) and prostaglandins (PGs) play a role in the pathological states such as 
inflammation, fever, pain, and cancer, as well as in proliferation and angiogenesis3. The 
oxygenation of arachidonic acid by a LOX or COX enzyme initiates the formation of LTs or 
PGs, respectively3. Each of the eicosanoid molecules has (or is likely to have) a specific 
physiological function depending on its environment.   
COX oxygenation of arachidonic acid leads to prostaglandins, which are made by most 
cells within the body. Since prostaglandins are not stored, they must be made de novo from 
arachidonic acid4.  This is thought to occur at the endoplasmic reticulum and nuclear membrane, 
where cPLA2, in response to specific stimuli, frees arachidonic acid from membrane 
phospholipids5. Free arachidonic acid acts as a substrate for cyclooxygenases to form the 
intermediate prostaglandin PGH2. From PGH2, individual synthases form PGE2, PGD2, PGF2, 
PGI2, and thromboxane (TxA2). These prostaglandins mediate inflammatory responses and play 
a role in vascular homeostasis through their respective G-protein-coupled receptors (GPCRs)3.  
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The 5-LOX oxygenation of arachidonic acid initiates formation of leukotrienes3. 5-LOX 
first oxygenates arachidonic acid to 5-HPETE that is then converted in a second LOX reaction to 
leukotriene A4 (LTA4). LTA4 can be hydrolyzed to leukotriene B4 (LTB4) by LTA4 hydrolase or 
can be conjugated with reduced glutathione by leukotriene C4 (LTC4) synthase. Both LTB4 and 
LTC4 are exported from the cell by specific transporters
6. The production of leukotrienes occurs 
in cells such as polymorphonuclear leukocytes, macrophages, and mast cells. 5-LOX is thought 
to be activated primarily in leukocytes which have migrated into or extravasated through 
epithelial tissues by pro-inflammatory stimuli7. Leukotrienes are critical potentiators of 
inflammatory responses through their GPCRs and are often associated with bronchoconstriction 
and asthma8,9. 
Aberrant COX and LOX activity is prominently associated with many types of human 
cancers such as prostate and colorectal cancers, with increased activation of 5-LOX10. Studies 
also show that COX-2 activation is associated with early stages of carcinogenesis11. Altered 
COX and LOX activity has been demonstrated in other inflammatory conditions such as 
atherosclerosis and Alzheimer’s disease (AD). In glioblastoma, the high expression 5-LOX and 
COX-2 jointly correlate with poor prognosis12. 
The spatial and temporal localization of COX-2 and 5-LOX is highly regulated and is 
correlated with inflammation. Formation of HKs requires co-localization of active COX-2 and 5-
LOX, because the COX-2 substrate (5S-HETE, made by 5-LOX) must be produced in close 
proximity to active COX-2 enzyme. Instances in which this might occur are when activated 
neutrophils producing 5S-HETE pass in close proximity to activated endothelial cells or when 
activated neutrophils producing 5S-HETE are exposed to a vessel wound site where COX-2 
expression has increased due to trauma. 
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The role of COX-2 and 5-LOX in inflammation: implications for hemiketals 
A number of studies suggest that the same enzymes are involved in the initiation and 
resolution of inflammation13–15. COX-2 expression during inflammation has been characterized 
as biphasic16. The early phase of COX-2 expression was shown experimentally to occur during 
onset of inflammation, with a second peak coinciding with the resolution phase. PGD2 synthesis 
by COX-2 was implicated in the resolution phase, with the non-enzymatic dehydration to the 
anti-inflammatory J-series of prostaglandins16. These prostaglandins reduce inflammation by 
inhibiting the production of cytokines and monocyte activation through activation of PPAR-
γ17,18. Due to the context-dependent action of molecules similar to HKs, investigating the 
physiological setting in which the HKs are formed may provide insight into their specific 
function as either pro-inflammatory or pro-resolving lipid mediators. 
In addition to leukotrienes, LOX activity also leads to the formation of lipoxins (LXs), 
which are formed through the subsequent activity of lipoxygenases. LXs act on LX-specific 
GPCRs to exert their anti-inflammatory activity, as well as act as antagonists of the pro-
inflammatory LT receptors18,19. The example of LX formation and function highlights the 
complex nature of inflammation regulation and provides support for the notion that the 
convergence of enzymatic pathways may be required for creating products that act as key 
regulators. 
Since both COX-2 and 5-LOX are known to play specific roles in both onset and 
resolution of inflammation, I hypothesize that the HKs function in same physiological contexts 
as prostaglandins, leukotrienes, and lipoxins to both drive the onset and establish the resolution 
of inflammation.  
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Co-expression of 5-LOX and COX-2 in inflammatory disease 
Since our lab has shown that HKs are formed via the convergence of 5-LOX and COX-2 
pathways, physiological systems where there is a co-expression of 5-LOX and COX-2 become 
immediately relevant. In most tissues COX-1 is expressed constitutively and COX-2 is involved 
in pathological processes. When stimulated, 5-LOX in neutrophils is activated. The 5-LOX 
expressing-neutrophils may interact with COX-2-expressing macrophages in the blood, or with 
COX-2 expressing vascular endothelium or in synovial fibroblasts. Neutrophils stimulated for 
COX-2 expression, then for activation of 5-LOX show the presence of 5S-HETE, LTB4, PGE2 
and HKE2 (unpublished data). At sites of vascular inflammation, neutrophils are recruited 
leading to another instance where cells expressing 5-LOX and COX-2 individually are in 
immediate proximity. The term “transcellular biosynthesis” can be applied to this type of HK 
production because neutrophil-derived 5S-HETE crosses to a different cell with activated COX-2 
in order to produce HKs. Due to this possible mechanism of HK formation, cell-based 
experimental models were chosen based on the ability of the specific cell to express COX-2 and 
the likelihood that the cell would encounter activated 5-LOX expressing neutrophils. 
 
Primary synovial fibroblasts as a model for testing HKE2 activity 
 
Rheumatoid arthritis is an inflammatory disease of the joints that involves synovial 
fibroblasts, macrophages, and lymphocytes20.  Synovial fibroblasts are cells of the intimal lining 
layer of synovial tissue. They play a role in the maintenance of joint integrity, but they also act as 
innate immune cells, attracting neutrophils and producing inflammatory cytokines downstream 
of  Toll-like receptor stimulation20. COX expression in synovial tissue from human patients 
correlates with mononuclear cell infiltration and RA synovial fibroblasts express more COX than 
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typical cells21. With the ability of synovial fibroblasts to attract 5-LOX expressing neutrophils, 
synovial fibroblasts from patients with rheumatoid arthritis are an example of where HKs might 
be made, and thus act. 
 
Endothelial cells as a model For testing HKE2 activity 
At a site of injury within the cardiovascular system, endothelial cells will encounter 5-
LOX expressing neutrophils during extravasation and COX-2 expressing macrophages during 
migration, in a manner similar to synovial fibroblasts encountering activated neutrophils22,23. The 
proximity of the leukocytes at the endothelium could lead to the production of HKs. Since 
products of the COX- 2 and 5-LOX pathways have been shown to regulate endothelial cell 
function and angiogenesis11, the effects of HKD2 and HKE2 on tubulogenesis were previously 
examined in the Schneider lab. Preliminary work showed that HKs stimulated the formation of 
endothelial capillary-like structures in mouse microvascular pulmonary endothelial cells in a 
dose-dependent manner (125 nM to 500 nM). The HKs also stimulated endothelial cell migration 
when used at 1 μM. The same studies show that neither HKD2 nor HKE2 (between 10 nM to 1 
μM) induced changes in intracellular calcium levels of the endothelial cells nor stimulated their 
proliferation2. For these reasons, primary HUVECs were a relevant model to examine possible 
effects of HKE2 activity. 
 
RAW 264.7 cells as a model for testing HKE2 activity  
 RAW 264.7 cells are mouse monocyte-like cells that can be stimulated with 
lipopolysaccharide (LPS) to express COX-2 and become macrophages. These cells can also 
phagocytosize bacterial particles and engulf 5-LOX expressing neutrophils during 
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efferocytosis24.  Due to their ability to express high levels of COX-2 and their proximity to 5-
LOX expressing neutrophils, macrophages are a relevant cell type in which to study the effects 
of HKE2.  
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CHAPTER II 
 
Preparation and Analysis of Synthetic HKE2 
 
Introduction 
Professor Claus Schneider first identified HKE2 and HKD2 by incubating synthetic 5S-
HETE with recombinant COX-2 in a phosphate buffered-saline (PBS) buffer at pH 8 as part of 
studies exploring the possible convergence of the 5-LOX and COX-2 pathways. He showed that 
5S-HETE, but not 5R-HETE, was a specific and efficient substrate for COX-2, and that 
oxygenation of 5S-HETE by COX-2 leads to the formation of a chemically unstable bicyclic 
diEP. This reaction is similar to the oxygenation of AA by COX-2 (which leads to the formation 
of the chemically unstable intermediate prostaglandin H2 [PGH2]) however where COX-2 
oxygenation of AA leads to the formation of a cyclopentyl ring, COX-2 oxygenation of 5S-
HETE leads to the formation of a seven membered ring due to enzymatic incorporation of one 
additional molecule of oxygen as compared to PGH2. Spontaneous nonenzymatic rearrangement 
of the diEP leads to the formation of HKE2 and HKD2 and Prof. Schneider demonstrated that the 
diEP acts as a substrate for hematopoietic prostaglandin D synthase (H-PGDS), leading to 
increased formation of HKD2, over nonenzymatic rearrangement alone
2. The reaction products 
were examined and collected using high pressure liquid chromatography (HPLC) with a diode 
array detector1,2. The structure of the collected products were elucidated using 1H-NMR. LC-
ESI-MS/MS methods were developed using the collected, purified products to characterize 
retention times and mass spectra.  To further study these novel eicosanoids, Prof. Sulikowski 
synthesized HKE2-methyl ester (HKE2-ME). To analyze the product we received from Prof. 
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Sulikowski, we dissolved the HKE2-ME film in 100% LC-MS grade methanol and using reverse 
phase high pressure liquid chromatography with a diode array detector, analyzed and purified the 
sample. With the final, purified product isolated we also sent HKE2, dissolved in DMSO, for 
GPCR screening with DiscoveRx against 168 GPCRs and 73 orphan receptors as agonist and 
antagonist. 
 
Results and discussion 
The HKE2-ME gave a UV maximum absorption of 236 nm and a retention time of 11 
min on reversed phase HPLC (Waters Symmetry Shield RP-18 column (2.1 × 100 mm; 3 μm; 
1.0 ml/min flow rate over 25 minutes; linear gradient of 80% acetonitrile to 20% acetonitrile in 
water each containing 10 mM NH4OAc). Under the same conditions, the free acid hemiketal E2  
(HKE2) had a retention time of 9.5 min
2. Since our lab has detected the HKE2 as a free acid in 
biological models, we sought to hydrolyze the HKE2-ME to the HKE2 for further biological 
testing.  Using 5% KOH, HKE2-ME was hydrolyzed, subsequently acidified for extracteion over 
solid phase. The hydrolysis product was confirmed to be HKE2 by LC-ESI-MS and 
1H-NMR. 
For subsequent routine preparation and purification of the compound, we used UV/Vis-HPLC 
and monitored the retention time of the compound and the presence of its characteristic 
absorbance of 236 nm (Figure 2).  The yield of HKE2 from the hydrolysis reaction of the HKE2-
ME with 5% KOH after extraction and purification was approximately 85%. Using the purified 
HKE2, verified by 
1H-NMR, we determined the molar extinction coefficient to be 11,000  M-
1cm-1.   With the HKE2 purified, we first examined the stability of HKE2 in RAW 264.7 cell 
culture medium, Dulbecco’s Modified Eagle Medium (DMEM) at 37 °C (similar to cell culture 
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conditions). We found that HKE2 levels were not significantly decreased until 4 h following 
incubation (Figure 3). 
  
Figure 2: Hemiketal E2-Methyl Ester (HKE2-ME) hydrolysis and purification. HKE2-ME was received from 
the lab of Professor Gary Sulikowski. The product was hydrolyzed with 5% KOH for 60 s at 23° C. The reaction 
was neutralized with 1 N HCl, and extracted by solid phase extraction. To analyze the compound before and after 
cleavage reverse phase high pressure liquid chromatography with a diode array detector was used. The HKE2-
ME, which was verified by 1H-NMR, has a characteristic retention time of 11 min. After hydrolysis, the 
hemiketal E2 (verified by 
1H-NMR) displays a characteristic retention time of 9.5 min. Multiple wavelengths 
(indicated by different color traces on the HPLC chromatograms) were monitored. HKE2 displays a characteristic 
absorbance at 236 nm arising from its conjugated diene moiety and is represented above by an orange trace.. 
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Figure 3: LC-ESI/MS2 analysis of hemiketal E2 (HKE2) stability. 25 ng of HKE2 in methanol (MeOH) was 
added to 37 °C  DMEM and incubated at 37 °C for various lengths of time. The medium was extracted with solid 
phase extraction cartridges and reactions were quantified against a known quantity of HKE2.  Error bars represent 
standard error of the mean for the integration of the RT 1.91 peak at various time points. Representative 
chromatograms are shown above the data (* = p < 0.01, unpaired t test, n = 3). 
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As HKE2 is formed by the crossing over of 5-LOX and COX-2, and has been found in the 
supernatant of human leukocyte preparations, we examined whether exogenously added HKE2 
could be found inside cells. The localization of HKE2 is relevant to its possible biological 
activity because a general understanding of localization may provide insight into where HKE2  
might act, for example through cell surface receptors or possibly at other sites within the cell (i.e. 
through electrophilic adduction). To understand where exogenous HKE2 localizes, HKE2 was 
added to culture medium on RAW 264.7 cells and incubated for various lengths of time at 37 °C. 
The cell medium was collected and extracted by solid phase. Cells were washed 5 times with 1x 
PBS, with the last of the 5 washes being collected and extracted by solid phase25. After cells 
were washed, the aqueous milieu of the cells was extracted by a modified Bligh and Dyer 
extraction procedure26. The extracts were analyzed by LC-ESI-MS-SRM to determine the 
presence of HKE2 inside or outside of the cells. While HKE2 could not be detected inside the 
cells (or in the PBS washes) HKE2 was somehow altered by cells, indicating that HKE2 may 
interact in some way with the RAW 264.7 cells, or a factor from the RAW 264.7 cells. We are 
uncertain as to what factor relating to these cells leads to changes in HKE2 structure. When 
HKE2 is analyzed by LC-ESI-MS/SRM, a characteristic peak at 1.86 min for m/z 399 to 151 is 
present. In the presence of cells, with increasing time the integration of the peak at 1.86 min 
decreases, while in a time-dependent manner a peak at 1.35 min appears (also with m/z 399 to 
151) (Figure 4). This transformation does not occur in the absence of cells. 
The activation of GPCRs would not require that HKE2 enter the cells, since GPCRs are 
expressed at the surface of cells. We tested HKE2 at a maximum concentration of 5 μM as both 
agonist (Table 1) and antagonist (Table 2). To look at the activation of cell surface receptors  
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Figure 4. LC-MS/MS analysis of hemiketal eicosanoid E2 (HKE2) in cell culture medium over time. (A) A 
characteristic peak at 1.86 min for m/z 399 to 151 is present (no cells). In the presence of cells, with increasing time 
the integration of the peak at 1.86 min decreases, while in a time-dependent manner a peak at 1.42 min appears (also 
with m/z 399 to 151). (B) Integration peaks at 1.87 min and 1.3 min after different lengths of incubation with RAW 
264.7 cells (n=2). The lines in (B) are derived from a single experiment and are shown only to visualize the trend of 
the loss of the peak at 1.86 min and the formation of the peak at 1.42 min. 
15 
 
  
Table 1:  Top hits for 5 μM hemiketal eicosanoid E2 (HKE2) from DiscoveRx GPCR Receptor Agonist 
Screen. CXCR4 or the Chemokine (C-X-C Motif) Receptor 4 showed 24% activity, while the HTR1B or the 5-
Hydroxytryptamine Receptor 1B showed 15%. 
16 
 
  
Table 2:  Top hits for 5 μM hemiketal eicosanoid E2 (HKE2) from DiscoveRx GPCR Receptor Antagonist 
Screen. HKE2 showed the antagonism of the following receptors at the percentages indicated in the table above: 
ADRA2B  or the Alpha 2B adrenergic receptor , CNR2 or Cannabinoid receptor 2, MC1R, MC3R, MC5R  or 
Melanocortin 1, 3, and 5 receptors (respectively), P2RY4 or Pyrimidinergic receptor P2Y, and TBXA2R or 
Thromboxane A2 receptor.     
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we sent HKE2 to DiscoveRx for screening using proprietary cell-based assays that monitor the 
activation of a GPCR in a homogenous, non‐ imaging assay format, using Enzyme Fragment 
Complementation (EFC) with β‐ galactosidase (β‐ Gal) as the functional reporter. The β‐ Gal 
enzyme is split into two inactive complementary portions (Enzyme Acceptor [EA] and Enzyme 
Donor [ED]) and is expressed as fusion proteins in the cell. The EA is fused to β‐ Arrestin and 
the ED is fused to the GPCR of interest. When the GPCR is activated and β‐ Arrestin is recruited 
to the receptor, ED and EA complementation occurs, restoring β‐ Gal activity. The β‐ Gal 
activity is measured using chemiluminescent detection reagents (PathHunter®). For agonist 
determination, proprietary cells were incubated with HKE2 to induce a response. Intermediate 
dilutions of HKE2 were made to generate 5X sample in assay buffer. To the cells 5 μL of 5x 
sample was added, and the cells were incubated at 37 °C or room temperature for 90 or 180 
minutes. For antagonist examination, cells were pre‐ incubated with HKE2, followed by agonist 
challenge at the EC80 concentration. An intermediate dilution of HKE2 was made to generate 5X 
sample in assay buffer. As in agonist mode, 5 μL of 5x sample was added to cells and incubated 
at 37°C or room temperature for 30 minutes. Then 5 μL of 6X EC80 agonist in assay buffer was 
added to the cells and incubated at 37°C or room temperature for 90 or 180 minutes.  
The DiscoveRx screening revealed that HKE2 showed activity at several receptors listed 
in Tables 1 and 2. The agonist table shows the percentage activity of HKE2 at the relevant 
receptors. Percent activity was calculated as follows, where RLU is a measure of luminosity:  % 
Activity = 100% x (mean RLU of test sample – mean RLU of vehicle control) / (mean MAX 
control ligand – mean RLU of vehicle control). The table also shows % CV, or the coefficient of 
variation, which is a measure of relative variability of the data sets.  For the receptor hits in 
agonist mode, it appears that HKE2 yields 24% activation of  CXCR4 (the receptor at which 
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HKE2 demonstrated the highest percentage activity), with a 6% coefficient of variation - as 
compared to 100% activity (set mathematically by the endogenous ligand, in this case CXCL12).  
While the value of further study of the effect of HKE2 at CXCR4 cannot be ruled out, this is not 
a robust hit. To study this further one might consider using cells such as HUVECs, which have 
been engineered to overexpress CXCR4 and perform dose response curves that examine higher 
concentrations of HKE2 than what were used in the DiscoveRx screen. Additionally, varying 
incubation time of HKE2 may also yield stronger activation of CXCR4 by HKE2. HKE2 was also 
examined as an antagonist, and percentage inhibition was determined as follows: % Inhibition = 
100% x (1 – (mean RLU of test sample – mean RLU of vehicle control) / (mean RLU of EC80 
control – mean RLU of vehicle control). The receptor at which HKE2 showed the greatest 
antagonist activity was the Thromboxane Receptor (TBXA2R). This data reflects that HKE2 is 
able to inhibit TBXA2R 30% (with a % CV of 1). Additional studies, such as monitoring the 
ability of HKE2 to inhibit platelet aggregation may be warranted to make more in depth 
conclusions about HKE2 as a TXA2R antagonist. The results from DiscoveRx in regards to 
HKE2 activity at GPCRs provide an excellent starting point for functional assays testing the 
effects of HKE2. 
 
Conclusions 
From this work, we conclude that synthetic HKE2 is structurally identical to the 
enzymatic HKE2 based on HPLC, MS/MS, UV-Vis, and NMR. We also determined that HKE2 
may have activity at GPCRs, but the activity of HKE2 at the receptors tested per DiscoveRx 
screen was modest. We can also conclude that HKE2 undergoes a chemical change that is 
dependent on RAW 264.7 cells. This finding suggests the need for a number of subsequent 
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studies such as those to determine what metabolite(s) form when HKE2 is transformed by RAW 
264.7 cells and the localization of HKE2 within the cell. Also, because HKE2  is a highly 
electrophilic compound that forms inside cells, whether HKE2 adducts to nucleophilic amino acid 
residues such as cysteine or serine should be examined.   
20 
 
Chapter III 
 
Testing the Effects of HKE2 in Primary Human Synovial Fibroblasts 
 
Introduction 
Primary human synovial fibroblasts, used in these experiments, are cells isolated from the 
joints of patients with rheumatoid arthritis (RA), which is a systemic autoimmune inflammatory 
disease characterized by synovial inflammation, as well as destruction of bone and cartilage2728.  
Synovial tissues isolated from patients with inflammatory arthritis produce high levels of PGs, 
and COX-2 is likely responsible for the increases in PGs 29,30. COX-2 is abundant in the 
endothelial cells of synovial blood vessels31, where activated neutrophils would circulate. The 
synovium in RA produces increased levels of PGE2. The PGs play critical roles in the dilatation 
and permeability of small blood vessels29. 
Because we wanted models that might reflect environments in which the HKs might be 
made, we focused on models where both increased 5-LOX and COX-2 expression or activity 
was important. In addition to increased levels of PGE2, synovial fibroblasts have been shown to 
attract neutrophils20, meaning that primary synovial fibroblasts are cells that would come in 
contact with 5-LOX expressing neutrophils during inflammation, through a mechanism that is, in 
part, dependent on COX-2 derived products29. Additionally, the lab of Professor Leslie Crofford 
has shown that microsomal prostaglandin E2 synthase (mPGES1) is upregulated in primary 
synovial fibroblasts and is, through a feed forward mechanism, regulated by PGE2 as well as 
responsible for PGE2 production. This suggests that COX-2 derived products regulate 
inflammation in primary synovial fibroblasts. Because this pathway is not fully elucidated, there 
appears to be value in investigating whether HKE2may act along this feed forward mechanism. 
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Results 
We examined the effects of HKE2 as it relates to regulation of mPGES1, by measuring 
RNA transcription of mPGES1 relative to GAPDH. Our results shows that 1 ng/mL IL-1β 
stimulation upregulated mPGES1, as would be expected as IL-1β is an inflammatory stimulus. 
We also measured the upregulation of IL-6, as a control since IL-6 transcription has been shown 
to increase downstream of IL-1β32. Preincubation with HKE2 does not significantly alter 
MPGES1 transcription resulting from IL-1β stimulation (Figure 5). We also investigated if 
exogenous HKE2 treatment would increase levels of COX-2. HKE2 did not increase levels of 
COX-2, nor did it potentiate COX-2 expression when pre-incubated with primary human 
synovial fibroblasts before IL-1β stimulation (Figure 6). Also, we investigated HKE2 effect on 
proliferation of primary synovial fibroblasts using the WST-1 assay. We examined the effects of 
HKE2 on fibroblast proliferation because studies have shown that COX-2 activation in 
fibroblasts may affect proliferation and invasiveness of certain cell types 33. We determined that 
HKE2 did not affect proliferation of primary synovial fibroblasts with or without IL-1β 
stimulation (Figure 7). Thus, HKE2 fails to exert any meaningful effect in our models of primary 
synovial fibroblast activation.  
 
Conclusions 
While primary synovial fibroblasts represent a model of inflammation in which HKE2 
might act, we did not detect any effect of HKs in the assays we performed.  This limited set of 
assays does not mean that HKs are not biological active, as there are a number of other activities 
where lipid mediators may be important. [Please elaborate on one or more of these.]  
Determining the effects of unknown endogenous compound is, to some extent, like finding a 
needle in a haystack. Occam’s razor would suggest cells able to produce these paracrine or 
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autocrine signaling molecules are the first that should be examined. In addition to examining the 
effect of HKE2 on cell types associated with inflammation, a continued examination of these cell 
types ability or produce HKE2 would be interesting to pursue. 
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Figure 5: RT-qPCR analysis of hemiketal E2 (HKE2) modulation of interleukin-1β induced changes to IL-6 
and mPGES-1 gene transcription in primary human synovial fibroblasts.  Changes in gene transcription are 
shown relative to the reference gene GAPDH. Error bars represent standard error of the mean (* = p < 0.01, 
unpaired t test, n = 3). 
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Figure 6: Western blot analysis of COX-2 expression as modulated by hemiketal eicosanoid E2 (HKE2) in 
human primary synovial fibroblasts. Primary synovial fibroblasts were treated with indicated concentrations of 
hemiketal E2 for 45 min then stimulated with 1 ng/mL IL-1β for 6 h at which point protein lysates were collected 
and subjected to Western blot analysis. (n =3).  
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Figure 7: WST-1 cell proliferation assay to measure the effects of hemiketal eicosanoid E2 (HKE2) on 
proliferation of primary human synovial fibroblasts. Primary synovial fibroblasts were treated with increasing 
concentrations of HKE2 in the presence and absence of interleukin 1β to measure cell proliferation at 24 h in 
treated cells versus control (Vehicle-treated) cells. Error bars represent standard error of the mean (n = 3). 
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CHAPTER IV 
 
Testing the Effects of Hemiketal E2 in Human Umbilical Vein Endothelial Cells 
 
Introduction 
Since both COX-2 and 5-LOX products have been implicated in endothelial cell 
regulation, in 2011 the Schneider lab tested the effects of HKs on mouse microvascular 
pulmonary endothelial cells2,34. The lab demonstrated that HKE2 and HKD2 potently stimulated 
tubulogenesis in mouse microvascular endothelial cells at nanomolar concentrations2.  For this 
reason, we hypothesized that HKE2 would also stimulate tubulogenesis, a step in angiogenesis in 
HUVECs. The steps of angiogenesis are (1) vascular sprouting, (2) tubule morphogenesis, (3) 
adaptation to tissue needs, and (4) vessel stabilization. During tubulogenesis a cell must establish 
apicobasal polarity. Tubulogenesis involves complex cellular interaction with extracellular 
matrix, along with cytoskeletal reorganization, and the underlying mechanisms of this process 
still require elucidation35,36. Several important variables in tubulogenesis are factors such as cell 
polarity35,37, cytoskeletal factors, and matrix metalloproteinases. 
Well-established angiogenesis assays use endothelial cells to measure cell proliferation, 
cell migration, and tube formation as a part of the overall process36,38,39.  While it is logical that 
HKs may exert an effect at any stage of angiogenesis, especially under inflammatory conditions 
such as wounding or cardiovascular disease, we chose to use tube formation as a measure of HK 
effect because of the positive results using mouse microvascular pulmonary endothelial cells, 
and in the event of a positive result it would be easier to focus in from the wider result of tube 
formation. 
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Results and discussion 
To examine the effect of HKE2 on tubulogenesis in HUVECs cell culture medium 
containing vehicle, various concentrations of HKE2, or complete endothelial cell culture medium 
containing 5% fetal bovine serum (FBS) was added to cells. HUVECs were allowed to incubate 
for 6 h under serum starved conditions (except for the positive control wells), at which point 
medium was removed and cells were fixed in formalin. The number of tubes per visual field 
were counted and quantified (Figure 8). Representative images are shown in Figure 9.  No 
visible difference between vehicle and HKE2 treated cells were seen, while cells treated with 
complete medium visibly formed more tubes. While not included in the quantification, multiple 
repeats of higher concentration HKE2 treatments were performed (1 μM and 10 μM). HKE2 
appeared to have no effect at the higher concentrations. HKE2 does not stimulate (or inhibit) 
tubulogenesis of primary HUVECs compared to no treatment.  
We also examined the effect of HKE2 on proliferation of HUVECs after 24 h exposure to 
concentrations of HKE2 ranging from 10 nM to 10 μM. HKE2 showed no effect on proliferation, 
neither stimulating nor inhibiting proliferation. We also examined if HKE2 effected proliferation 
in HUVECs that we stimulated with 1 ng/mL IL-1β. Again, HKE2 demonstrated no effect on 
proliferation in HUVECs (Figure 10). 
 
Conclusions 
While HKE2 stimulated tubulogenesis in primary mouse microvascular endothelial cells, 
we were unable to replicate this result in HUVECs. We also did not see that HKE2 effected 
proliferation of HUVECs over a broad range of concentrations after 24 h. As in the primary  
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Figure 8: Hemiketal E2 (HKE2) effects on tubulogenesis in human umbilical vein endothelial cells 
(HUVECs). HUVECs were seeded at 2.5x103 cells per wells onto matrigel and allowed to grow in the presence 
and absence of no treatment, vehicle, HKE2, and complete endothelial cell medium containing 10% FBS (n = 3). 
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Figure 9: Quantification of hemiketal E2 (HKE2) effects on tubulogenesis in human umbilical vein 
endothelial cells (HUVECs). HUVECs were seeded at 2.5x103 cells per wells onto matrigel and allowed to grow 
in the presence and absence of no treatment, vehicle, HKE2, and complete endothelial cell medium containing 
10% FBS.  After 6 h the cells were fixed with formalin. Each well was imaged using light microscopy, and the 
number of fully closed tubelike structures was tallied for each condition. Error bars represent standard error of the 
mean (* = p < 0.02, unpaired t test, n=3). 
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Figure 10: WST-1 cell proliferation assay to measure the effects of hemiketal eicosanoid E2 (HKE2) on 
proliferation of human umbilical vein endothelial cells (HUVECs). HUVECs were treated with increasing 
concentrations of HKE2 in the presence and absence of interleukin 1β to measure cell proliferation at 24 h in 
treated cells versus control (vehicle-treated) cells. Error bars represent standard error of the mean (n=3). 
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synovial fibroblasts, it would be remiss to conclude that HKE2 does not produce a biological 
response in HUVECs. The conclusion is simply that in the models tested HKE2 does not produce 
the biological response that we were measuring. Initial data (not shown) suggests that 500 nM 
HKE2 may stimulate ERK1/2 phosphorylation, as well as P38 phosphorylation. This means that 
there is a possible biological effect of HKE2, but that the circumstances under which HKE2 acts 
is more complex than the system we modeled.   
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CHAPTER V 
 
Testing the Effects of Hemiketal E2 in RAW 264.7 Cells 
 
Introduction 
The RAW 264.7 cell line is a cell line derived from murine tumors that were induced 
with Abelson leukemia virus. This cell line exhibits many properties of macrophages, for 
example it can take up neutral red dye, can synthesize and secrete lysozyme, can phagocytose 
latex and zymosan beads40, and can be induced to robustly express COX-2. Griesser, et al. have 
shown that RAW 264.7 cells are able to synthesize HKs when the 5-LOX product 5S-HETE is 
added exogenously and that human leukocyte samples (containing COX-2 expressing 
macrophages and 5-LOX expressing neutrophils) can be stimulated to produce HKs2. For these 
reasons we conjectured that RAW 264.7 cells would be a suitable model for testing the 
biological effects of HKE2.  
Since eicosanoids modulate NFkB signaling in RAW 264.7 cells41, we used RAW 264.7 
cells with a stable transfection of pNFkB-MetLuc2 (reporter vector) to monitor NFkB activation. 
This vector has NFkB binding consensus enhancer sequences cloned in the promoter region, 
such that when NFkB is activated and translocates to the nucleus, the activated complex will 
bind to the cloned region and initiate the transcription of the secreted Metridia luciferase reporter 
gene.  COX-2 expression is highly inducible in RAW 264.7 cells, and has shown to be regulated 
by eicosanoids. It has also been demonstrated that PGE2, a COX-2 product to which HKE2 bears 
structural similarity, mediates suppression of phagocytosis in macrophages42. Due to the 
established connection of macrophage regulation by eicosanoids, the proximity of COX-2 
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expressing macrophages to 5-LOX expressing neutrophils, we believed RAW 264.7 cells to be a 
relevant model in which to examine HKE2 activity. 
 
Results and discussion 
To examine the effect of HKE2 on COX-2 expression in RAW 264.7 cells, cells were 
treated with various concentration of HKE2 (as indicated) after 45 min 100 ng/mL LPS was 
added (or not). HKE2 did not effect COX-2 expression in stimulated or unstimulated RAW 264.7 
cells (Figure 11). Similary, enzyme-linked immunosorbent assays (ELISAs) were carried out 
using RAW 264.7 cells, and the same treatment conditions as mentioned previously, but the 
supernatant was collected to measure levels of PGE2. PGE2 levels, relatively, reflect COX-2 
expression based on treatments (Figure 12).  
We also examined the ability of HKE2 to modulate NFkB activation in pNFkB-MetLuc2 
stably transfected RAW 264.7 cells. Cells were treated with the indicated concentrations of 
HKE2 for 45 min. After 45 min cells were stimulated with1 ng/mL LPS to activate NFkB. This 
cell line expresses NFkB binding consensus enhancer sequences cloned in the promoter region. 
When NFkB is activated and translocates to the nucleus, the activated complex will bind to the 
cloned region and will initiate the transcription of the secreted Metridia luciferase reporter gene. 
Luciferase activity is measured in the supernatant (Figure 13). Our results show that HKE2 has 
no effect on NFkB activation. We also found that HKE2 independent of LPS has no effect on the 
activation of NFkB (data not shown).  
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Figure 11: Western blot analysis of COX-2 expression as modulated by hemiketal eicosanoid E2 (HKE2) in 
RAW 264.7 cells. RAW 264.7 cells were treated with indicated concentrations of hemiketal E2 for 45 min then 
stimulated with lipopolysaccharide from E. coli 0111:B4 for 6 h at which point protein lysates were collected and 
subjected to Western blot analysis.  The quantification of the Western blot analyses is shown above. Error bars 
represent standard error of the mean (n=3). 
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Figure 12: ELISA analysis of PGE2 levels as modulated by hemiketal eicosanoid E2 (HKE2) in RAW 
264.7 cells. RAW 264.7 cells were treated with indicated concentrations of hemiketal E2 for 45 min then 
stimulated with lipopolysaccharide from E. coli 0111:B4 for 6 h at which point culture medium was collected 
and subjected to ELISA. Error bars represent standard error of the mean (* = p < 0.01, unpaired t test, n=2). 
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Figure 13: Effect of hemiketal eicosanoid E2 (HKE2) effect on NFκB activation in pNFκB-MetLuc2 stably 
transfected RAW 264.7 cells. To interrogate activation of NFκB by HKE2 was preincubated with pNFκB-
MetLuc2 stably transfected RAW 264.7 cells at the above described concentrations. Cells were then stimulated 
with 1 ng/mL lipopolysaccharide from E. coli 0111:B4. Error bars represent standard error of the mean (p<0.01, 
unpaired t test, n=3). 
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To examine the effect of HKE2 on proliferation of RAW 264.7 cells after 24 h exposure to 
concentrations of HKE2 ranging from 10 nM to 10 μM. HKE2 showed no effect on proliferation, 
neither stimulating nor inhibiting proliferation. We also measured proliferation in RAW 264.7 
cells that we stimulated with 100 ng/mL LPS. Again, HKE2 demonstrated no effect on 
proliferation in RAW 264.7 cells  (Figure 14). 
We also measured the effect of HKE2 on phagocytosis of fluorescently labeled E. coli 
particles. We selected a model system designed to quantitate how HKE2 might effect phagocytic 
function of RAW 264.7 cells. The system used was selected to follow the internalization of a 
foreign, fluorescently labeled E. coli particles. We detected intracellular fluorescence emitted by 
the engulfed particles, as well as the effective fluorescence quenching of the extracellular probe 
(i.e. the particles not engulfed). RAW 264.7 cells were incubated with HKE2 for 1 h, after which 
fluorescently tagged E.coli particles were added to the cells, thus stimulating phagocytosis. We 
found that HKE2 does not appear to effect phagocytosis in RAW 264.7 cells (Figure 15). I will 
note this assay is worth repeating, as these trials were part of preliminary searches for possible 
HKE2 activity. While we saw no apparent effect of HKE2, the appropriate negative control of 10 
μM Cytochalasin D incubation (to prevent phagocytosis) is missing from the assay. 
 
Conclusions 
HKE2 does not appear to modulate NFkB, COX-2 expression, or PGE2 levels in RAW 264.7 
cells when exogenously administered and preincubated with this cell line 45 min prior to the 
addition of LPS. However, there are non-canonical pathways leading to the activation of NFkB 
and upregulation of COX-243. It is possible that HKE2 might effect these inflammatory markers 
through a non-canonical mechanism. While we posit the HKE2 plays a role in inflammation,  
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Figure 14: WST-1 cell proliferation assay to measure the effects of hemiketal eicosanoid E2 (HKE2) on 
proliferation of RAW 264.7 cells. RAW 264.7 cells were treated with increasing concentrations of HKE2 in the 
presence and absence of 100 ng/mL lipopolysaccharide from E. coli 0111:B4 to measure cell proliferation at 24 h 
in treated cells versus control (Vehicle-treated) cells. Error bars represent standard error of the mean (n=3). 
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Figure 15: Fluorescent assay to measure the effects of hemiketal eicosanoid E2 (HKE2) on phagocytosis of 
fluorescently labeled E. coli particles. RAW 264.7 cells were treated with increasing concentrations of HKE2 
for 1 h, at which point the fluorescently labeled E. coli particles were added. To measure the effect of HKE2 on 
phagocytosis by RAW 264.7 fluorescence was monitored. Error bars represent standard error of the mean (n=2). 
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understanding the role of HKE2 in non-canonical signaling may be worth investigating further. 
HKE2 also does not appear to effect proliferation of RAW 264.7 cells or the ability of RAW 
264.7 cells to phagocytose fluorescently tagged E. coli particles.   
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CHAPTER VI 
 
Materials and Methods 
 
Cell lines, cell culture and reagents 
Primary synovial fibroblasts were a gift of Dr. Leslie Crofford (Professor of Pathology, 
Microbiology, and Immunology, Vanderbilt University Medical Center). Primary, pooled donor 
HUVECs were purchased from Lonza (USA). RAW 264.7 cells were obtained from ATCC 
(Manassas, VA). Primary synovial fibroblasts were maintained in Dulbecco’s Modified Eagle 
Medium (Invitrogen, Carlsbad, CA) supplemented with 20% fetal bovine serum (Gemini Bio 
Products, West Sacramento, CA), 100 U/mL penicillin, and 100 μg/ mL streptomycin 
(Invitrogen).  HUVECs were maintained in EGM-2 medium, supplemented with human 
Epidermal Growth Factor, Vascular Endothelial Growth Factor, R3-Insulin-like Growth Factor-
1, Ascorbic Acid, Hydrocortisone, human Fibroblast Growth Factor-Beta, Heparin, Fetal Bovine 
Serum, and Gentamicin/Amphotericin-B.  RAW 264.7 cells were maintained in Dulbecco’s 
Modified Eagle Medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum 
(Gemini Bio Products, West Sacramento, CA), 100 U/mL penicillin, and 100 μg/ mL 
streptomycin (Invitrogen). All cells were maintained at 37 °C in an atmosphere of 5% CO2 at a 
confluence of 80% or less.  
 
HPLC, LC-MS/MS and analytical reagents 
 HKE2 was analyzed and purified by UV/Vis-HPLC using a Waters Symmetry C18 
column (4.6 x 250 mm; 5 μm) eluted with a gradient of 20% acetonitrile (Sigma) to 70% 
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acetonitrile in 0.01% aqueous acetic acid over 25 min. Elution of the products was monitored 
using an Agilent 1200 diode array detector. 
A TSQ Vantage Triple Stage Quadrupole LC/MS Mass Spectrometer (Thermo Scientific) 
with an electrospray interface was linked to an Agilent 1100 series HPLC and operated in the 
negative ion mode. Settings for sheath and auxiliary gas pressures, temperature, and interface 
voltage were optimized based on previous experiments2. A Waters Symmetry Shield C18 3.5 μm 
column (2.1 x 150 mm) was used with a linear gradient of acetonitrile/water, 10 mM NH4OAc 
(5/95; solvent A) to acetonitrile/water, 10 mM NH4OAc (95/5 by volume solvent B) at 0.5 
mL/min within 5 min. For HKE2 the transition m/z 399  151 was monitored in the negative 
ion SRM mode. 
 
Tubulogenesis assay 
For the Matrigel-based tubulogenesis assay capillary-like structure formation of 
HUVECs was analyzed as number of closed tube-like structures formed38. Cooled 96-well plates 
were coated with 50 μL of BD Matrigel Matrix Growth Factor Reduced (BD Biosciences) and 
incubated for 30 min at 37 °C. Wells were fixed in formalin after 6 h and number of tube-like 
structures was quantified using images from a Nikon Eclipse 50i microscope using a 10x 
objective. Images were processed using ACT-1C Software. 
 
WST-1 cell proliferation assay 
The effects of HKE2 on proliferation in primary synovial fibroblasts, HUVECs, and 
RAW 264.7 cells were examined using the WST-1 assay. Per manufacturer’s instruction 100 μl 
per well of cells (5.0 x 103 cells per well for primary synovial fibroblasts, 2.5 x 104 cells per well 
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for HUVECs, and 4.0 x 104 for RAW 264.7 cells) were added in a 96-well plate, and incubated 
in serum free medium for 24 h in the presence or absence of varying concentratios of HKE2 (as 
indicated), with or without inflammatory stimulus (1 ng/mL IL-1β for synovial fibroblasts or 100 
ng/mL LPS for RAW 264.7 cells). After 24 h, 10μL of WST-1 reagent was added to each well, 
and cells were incubated for another 4 hours, per manufacturer’s instructions. The absorbance of 
the samples was then measured at 490nm with a microplate reader (Molecular Device, 
California) after shaking for 1 min against the blank, a background control. Each assay was run 
with technical triplicates, and was repeated 3 separate times. Cell proliferation assays were in 
triplicates. 
 
Western blot analysis 
For measuring COX-2 expression cells were plated on 10-cm cell culture dishes and 
allowed to grow for 48 h. The cell culture medium was removed, cells were washed, and serum 
free medium containing various concentration of HKE2 was added. After 45 min, 1 ng/mL IL-1β 
for synovial fibroblasts or 100 ng/mL LPS for RAW 264.7 cells was added. Cells were allowed 
to incubate for 6 hours, at which point the medium was removed, cells were washed and then 
scraped from the cell culture plate into 6 mL cold PBS using a cell lifter (Corning Incorporated, 
Corning, NY). Cells were then centrifuged at 1000 xg for 5 minutes. The PBS supernatant was 
aspirated and the cell pellet was resuspended in cold PBS followed by centrifugation at 5000 
RPM for 5 minutes to wash the cells. Cell lysates were prepared by aspirating the PBS 
supernatant and lysing the cells in an appropriate volume of RIPA buffer containing protease 
inhibitors (Roche) and phosphatase inhibitors (Roche). Protein concentration of cell lysates was 
determined using the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL) according to the 
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manufacturer’s instructions. Cell lysate samples were then diluted into NuPAGE LDS Sample 
Buffer (4X) (Novex, Carlsbad, CA) and boiled at 95 °C for 10 minutes. Cell lysate samples were 
loaded on 10% SDS-PAGE gel and resolved via electrophoresis at 100 V for approximately 1.5 
hours in sodium dodecyl sulfate (SDS) buffer (Novex). After gel electrophoresis samples were 
transferred overnight onto nitrocellulose membranes (Whatman, Little Chalfront, UK) by 
electrophoresis at 10 V in SDS/Glycine Buffer (Bio-Rad, Hercules, CA) with 20% methanol 
(Sigma-Aldrich). The membranes were probed with the mouse monoclonal anti-COX-2 (aa 684-
598) (1:1000 dilution; Cayman Chemical, Ann Arbor, MI ) and  mouse monoclonal anti-GAPDH 
(1:2000 dilution; Abcam, Cambridge, UK). Following primary antibody incubation, membranes 
were incubated with horseradish peroxidase (HRP)-conjugated polyclonal anti-mouse or anti-
rabbit immunoglobulin (IgG) (1:10,000 Promega, Madison, WI) and then visualized using ECL 
Prime Western Blotting Detection Reagent (Amersham, Buckinghamshire, UK).  
 
PGE2 ELISA 
RAW 264.7 cells were stimulated and treated with HKE2 for 45 min then stimulated with 
100 ng/mL LPS for 6 h. Supernatant was removed, spun at 1000 x g for 10 min at 4 °C for 10 
min to pellet debris. The amount of PGE2 in the supernatant was determined using PGE2 ELISA 
Kit – Monoclonal (Cayman Chemical).  
 
NFkB reporter assay 
The RAW 264.7 cells were stable transfected by Rebecca Edwards in the Claus Schneider 
group with a pNFkB-MetLuc2 (reporter vector) to monitor NFkB activation. This  pNFkB-
MetLuc2 vector has NFkB binding consensus enhancer sequences cloned in the promoter region. 
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This means that when NFkB is activated and translocates to the nucleus, the activated complex 
binds the cloned region and initiates the transcription of the secreted Metridia luciferase reporter 
gene (Clontech Laboratories Inc., California). 
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